AC Immune SA (ACIU) has released an update.
AC Immune SA’s Alzheimer’s candidate, ACI-35.030, now known as JNJ-2056, has been granted Fast Track designation by the FDA, signaling a significant advance in the potential treatment of the disease. The Phase 2b ReTain trial, fully funded and conducted by Janssen Pharmaceuticals, aims to study the effects of JNJ-2056 on preventing cognitive impairment in individuals with preclinical Alzheimer’s. This development marks a pivotal moment for AC Immune SA as it strives to innovate and create convenient, accessible treatments for neurodegenerative diseases.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
